GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
400K liters of plasma production capacity per annum
- 400K liters of plasma production capacity per annum
YONGIN, South Korea, Dec. 5, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced on December 6th that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company's overseas plant construction projects. - Backed by the Indonesian government's proactive support, the groundbreaking for what will become the nation's first-ever plasma fractionation plant was held after only 6 months following the Indonesian government's decision to approve the construction by GC Biopharma in June.
- With the maximum capacity of 400 thousand liters of plasma fractionation a year, the plant aims to commence operation by 2027.
- In fact, GC Biopharma is the only company worldwide that has completed the construction of plasma-derived products plant in the overseas market.